PCSK9 and hemorrhagic stroke: [38] In a prespecified secondary analysis of the FOURIER trial, focusing on clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab, there was a similar adjusted risk of hemorrhagic stroke (<1%), regardless of the achieved LDL-cholesterol concentration, including in the 2669 patients who achieved an LDL-cholesterol concentration of less than 0·5 mmol/L (19.3 mg/dL) at 4 weeks.